Nanjing King-friend Biochemical Pharmaceutical Co Ltd (603707) — Net Asset Quality Index
Nanjing King-friend Biochemical Pharmaceutical Co Ltd (603707) has a Net Asset Quality Index of 65.4% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥10.69 Billion minus total liabilities of CN¥3.71 Billion yields net assets of CN¥6.99 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Check 603707 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
Nanjing King-friend Biochemical Pharmaceutical Co Ltd Net Asset Quality Index Over Time (2013–2025)
This chart shows how Nanjing King-friend Biochemical Pharmaceutical Co Ltd's Net Asset Quality Index has evolved across 13 annual periods from 2013 to 2025. As of March 2026, the index stands at 65.4%, representing net assets of CN¥6.99 Billion against total assets of CN¥10.69 Billion CNY. See Nanjing King-friend Biochemical Pharmace working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for Nanjing King-friend Biochemical Pharmaceutical Co Ltd (2013–2025)
The table below presents the year-by-year Net Asset Quality Index for Nanjing King-friend Biochemical Pharmaceutical Co Ltd from 2013 to 2025, covering 13 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see Nanjing King-friend Biochemical Pharmace stock valuation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 66.7% | CN¥6.90 Billion | CN¥10.34 Billion | CN¥3.44 Billion | ▼ -1.5 pp |
| 2024 | 68.2% | CN¥6.49 Billion | CN¥9.51 Billion | CN¥3.02 Billion | ▲ +7.3 pp |
| 2023 | 60.9% | CN¥5.80 Billion | CN¥9.52 Billion | CN¥3.73 Billion | ▼ -0.7 pp |
| 2022 | 61.6% | CN¥6.17 Billion | CN¥10.01 Billion | CN¥3.84 Billion | ▼ -4.1 pp |
| 2021 | 65.8% | CN¥5.40 Billion | CN¥8.22 Billion | CN¥2.81 Billion | ▲ +17.2 pp |
| 2020 | 48.5% | CN¥3.74 Billion | CN¥7.72 Billion | CN¥3.98 Billion | ▼ -10.7 pp |
| 2019 | 59.2% | CN¥3.00 Billion | CN¥5.08 Billion | CN¥2.07 Billion | ▼ -12.0 pp |
| 2018 | 71.2% | CN¥2.42 Billion | CN¥3.40 Billion | CN¥981.21 Million | ▼ -5.0 pp |
| 2017 | 76.2% | CN¥2.05 Billion | CN¥2.69 Billion | CN¥642.50 Million | ▼ -10.2 pp |
| 2016 | 86.3% | CN¥1.31 Billion | CN¥1.52 Billion | CN¥208.09 Million | ▲ +2.1 pp |
| 2015 | 84.2% | CN¥1.09 Billion | CN¥1.30 Billion | CN¥204.72 Million | ▲ +17.2 pp |
| 2014 | 67.0% | CN¥1.03 Billion | CN¥1.54 Billion | CN¥508.26 Million | ▼ -21.0 pp |
| 2013 | 88.0% | CN¥1.02 Billion | CN¥1.16 Billion | CN¥138.91 Million | — |